Morningside Group is a private investment group founded in 1986 by the Chan family of Hong Kong. It is primarily engaged in private equity and venture capital investments. The group is known for its long-term investment approach and has a significant focus on life sciences, healthcare, technology, and other high-growth sectors globally. Morningside often invests in early-stage companies and supports them through various stages of development, leveraging its deep industry expertise and global network. They are recognized for backing innovative entrepreneurs and transformative technologies.
Serves as a primary hub for North American venture capital and private equity investments, particularly in the biotech, pharmaceutical, and technology sectors. It's a center for deal sourcing, due diligence, and portfolio company support in the region.
Located in the Kendall Square area, a globally recognized nexus for biotechnology and pharmaceutical innovation, surrounded by leading universities (like MIT), research institutions, and numerous life science companies.
Characterized by an intellectually rigorous, entrepreneurial, and collaborative environment. The culture likely emphasizes deep scientific and market analysis, long-term vision, and active partnership with portfolio companies.
Its location in Cambridge places Morningside at the heart of the US East Coast's biotech and innovation ecosystem, facilitating access to cutting-edge research, talent, and investment opportunities.
Morningside Group supports its global investment activities through strategically located offices in major innovation and financial centers, including North America (e.g., Cambridge/Boston) and Asia (e.g., Hong Kong, Shanghai). This presence enables them to source diverse investment opportunities, conduct thorough due diligence with local insights, provide hands-on support to their portfolio companies worldwide, and engage with various innovation ecosystems.
One Main Street, Suite 1250
Cambridge
MA
USA
Address: Level 33, Man Yee Building, 68 Des Voeux Road Central, Central, Hong Kong
Coordinates investment strategies in Asia-Pacific, leverages local market knowledge, and manages relationships with regional partners and portfolio companies.
Address: 8 Corporate Avenue, 222 Hubin Road, Huangpu District, Shanghai, China
To identify and capitalize on growth opportunities within China's rapidly evolving economy and support local entrepreneurs.
Address: 2 Liberty Square, 11th Floor, Boston, MA 02109, USA (Note: Address for Morningside Technology Advisory, related entity)
Supports North American investment activities, potentially with a focus on different technology verticals or advisory functions.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Morningside Group' leadership includes:
Morningside Group has been backed by several prominent investors over the years, including:
Specific executive movements within private investment firms like Morningside Group are not always widely publicized unless they involve very senior roles or public announcements related to new fund establishments or significant portfolio company involvement. Public information on hires/exits for the core investment team is limited for the past 12 months.
Discover the tools Morningside Group uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Morningside Group likely uses common corporate email formats. Based on industry standards and common patterns for investment firms, the most probable formats would involve combinations of first name, last name, and initials.
flast@morningside.com (e.g., jdoe@morningside.com) or first.last@morningside.com
Format
jdoe@morningside.com
Example
80%
Success rate
PR Newswire • March 7, 2024
Adlai Nortye Biopharma Co., Ltd., a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, in which Morningside Group is a significant pre-IPO shareholder, announced the pricing of its initial public offering. This highlights Morningside's role in funding and supporting biotech companies through to public markets....more
BioSpace • February 26, 2024
Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, where Morningside is a key investor, reported its financial results. This demonstrates ongoing involvement and oversight in its portfolio companies....more
GlobeNewswire • July 13, 2023
Rona Therapeutics, a biotech company dedicated to pioneering the next generation of RNA medicines, announced the successful completion of a $33 million Series A financing. The round included new investors like Morningside Ventures, aimed at advancing its platform and pipeline....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Morningside Group, are just a search away.